SCYNEXIS Reports First Quarter 2018 Financial Results and Provides Company Update

Enrollment complete in Phase 2b DOVE study in VVC; on-track for top-line data by July 2018 Phase 3 registration program in VVC planned for the fourth quarter of 2018 IV SCY-078 program continues to advance; Phase 1 study with liposomal formulation expected to initiate in the third quarter of 2018


Leave a Reply

Your email address will not be published.